Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022)

Abstract

Abstract: Cancer being one of the leading causes of death among non-communicable diseases, has already posed a heavy burden on the world health system. Chemotherapy is one of the most effec-tive approaches for cancer treatment, but multidrug resistance, lack of efficacy, and toxic side ef-fects hamper efficacious cancer chemotherapy, creating an urgent need to develop novel, more ef-fective and less toxic anticancer therapeutics. Quinoxalines, as fascinating structures, constitute an important class of heterocycles in drug discovery. Quinoxaline hybrids could exert anticancer ac-tivity through diverse mechanisms and possess profound in vitro and in vivo efficacy against vari-ous cancers, including multidrug-resistant forms. Thus, quinoxaline hybrids represent useful tem-plates for the control and eradication of cancer. The purpose of the present review article is to pro-vide an emphasis on the recent developments (Jan. 2017-Jan. 2022) in quinoxaline hybrids with in-sights into their in vitro and in vivo anticancer potential as well as structure-activity relationships (SARs) to facilitate further rational design of more effective candidates.